Compound · nebivolol
T1Pharmaceutical

Nebivolol

Third-generation beta-blocker with high beta-1 selectivity and additional nitric oxide (NO) potentiation via stimulation of endothelial NO synthase. The NO-mediated vasodilation distinguishes it from older beta-blockers that worsen peripheral vascular resistance. Does not impair glucose metabolism or lipid profiles at therapeutic doses, unlike non-selective beta-blockers.

Half-life
12-19 hours
Bioavailability
12% (extensive metabolizers) to 96% (poor metabolizers)
Route
oral
Evidence tier
T1 — Multiple RCTs
Optimization pillars
cellular-health
References
3 peer-reviewed
Dose ranges

Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.

conservative
2.5 mg/day
Starting dose
moderate
5 mg/day
Standard antihypertensive
aggressive
10–20 mg/day
Maximum dosing
Monitoring
  • lipid-panel
  • fasting-glucose
  • creatinine
  • egfr
  • hematocrit
Contraindications
  • severe-bradycardia
  • heart-block
  • decompensated-heart-failure
  • severe-hepatic-impairment
  • bronchospasm
References
  • PMID:16228159Nebivolol: a review of its use in the management of hypertension and chronic heart failureDrugs, 2005
  • PMID:15592319Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide releaseAnn Intern Med, 2004
  • PMID:21073365Nebivolol versus other beta-adrenergic blockers: comparison of hemodynamics and clinical outcomesAm J Cardiovasc Drugs, 2010
Notes

Nebivolol breaks every rule that made beta-blockers undesirable for active people. Traditional beta-blockers reduce exercise capacity, impair fat metabolism, worsen insulin sensitivity, and cause fatigue. Nebivolol does none of those things at standard doses because its NO-potentiating mechanism offsets the peripheral vasoconstriction that older beta-blockers produce. You get heart rate control without metabolic penalty. For someone on TRT who develops elevated resting heart rate or blood pressure — a common and undertreated issue — nebivolol is the beta-blocker that does not undo the metabolic benefits of hormone optimization. The CYP2D6 polymorphism creates a tenfold bioavailability range between extensive and poor metabolizers. Dose to heart rate response, not to label.

This is not medical advice

Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.

See Nebivolol in a protocol matched to you

OPTIMIZE · a protocols.is product